Overview Performance Dividends Peer Group Options

(MLYS) Mineralys Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6031701013

MLYS: Hypertension, Kidney, Disease, Treatment, Medication, Inhibitor

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cardiorenal diseases driven by dysregulated aldosterone. Their lead product candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor designed to address conditions such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company has initiated a Phase 2 trial for lorundrostat in patients with stage 2 to 3b chronic kidney disease and hypertensive patients, and a pivotal clinical program for uncontrolled or resistant hypertension. Formerly known as Catalys SC1, Inc., Mineralys Therapeutics was renamed in May 2020 and is headquartered in Radnor, Pennsylvania.

From a financial perspective, Mineralys Therapeutics has a market capitalization of $476.43M, with a price-to-book ratio of 2.48. The company currently operates at a loss, as indicated by a return on equity of -92.97, reflecting its early-stage development focus. There is no earnings data available, suggesting the company is pre-revenue.

Based on the provided technical and fundamental data, here is a 3-month forecast for Mineralys Therapeutics, Inc. (NASDAQ:MLYS): The stock is currently trading at $9.96, slightly below its 20-day SMA of $9.84 and 50-day SMA of $10.68, but above its 200-day SMA of $12.13. This indicates potential short-term bearish momentum but long-term bullish trends. The Average True Range (ATR) of 0.79 suggests moderate volatility. In the next three months, the stock may face resistance around the $10.68 level (SMA50) and support near $9.84 (SMA20). If the price breaks below the SMA200 at $12.13, it could signal a longer-term downtrend. Conversely, a rebound above the SMA50 might indicate a bullish reversal. Given the negative return on equity and lack of earnings, investor sentiment may remain cautious, potentially impacting price movements. The stocks performance will likely hinge on clinical trial outcomes and broader market conditions.

Additional Sources for MLYS Stock

News: Wall Street Journal Benzinga Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

MLYS Stock Overview

Market Cap in USD 456m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2023-02-10

MLYS Stock Ratings

Growth 5y -19.9%
Fundamental -64.1%
Dividend 0.0%
Rel. Strength Industry 22.4
Analysts 4.75/5
Fair Price Momentum 12.56 USD
Fair Price DCF -

MLYS Dividends

No Dividends Paid

MLYS Growth Ratios

Growth Correlation 3m -28.7%
Growth Correlation 12m -31.6%
Growth Correlation 5y -39%
CAGR 5y -5.39%
CAGR/Max DD 5y -0.08
Sharpe Ratio 12m -0.60
Alpha 2.16
Beta 1.04
Volatility 136.51%
Current Volume 1295.2k
Average Volume 20d 384.8k
What is the price of MLYS stocks?
As of March 15, 2025, the stock is trading at USD 14.25 with a total of 1,295,203 shares traded.
Over the past week, the price has changed by +35.46%, over one month by +39.16%, over three months by +17.19% and over the past year by +13.10%.
Is Mineralys Therapeutics a good stock to buy?
No, based on ValueRay Fundamental Analyses, Mineralys Therapeutics (NASDAQ:MLYS) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -64.13 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MLYS as of March 2025 is 12.56. This means that MLYS is currently overvalued and has a potential downside of -11.86%.
Is MLYS a buy, sell or hold?
Mineralys Therapeutics has received a consensus analysts rating of 4.75. Therefor, it is recommend to buy MLYS.
  • Strong Buy: 6
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for MLYS stock price target?
According to ValueRays Forecast Model, MLYS Mineralys Therapeutics will be worth about 14.1 in March 2026. The stock is currently trading at 14.25. This means that the stock has a potential downside of -1.12%.
Issuer Forecast Upside
Wallstreet Target Price 32 124.6%
Analysts Target Price 32.6 128.6%
ValueRay Target Price 14.1 -1.1%